H.R. 2416 · 114th Congress

To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.

Stage
In committee
Sponsor
Michael Burgess
Introduced
2015-05-19
Latest action
2015-05-22 · Referred to the Subcommittee on Health.

Action history

  1. 2015-05-22Referred to the Subcommittee on Health.
  2. 2015-05-19Introduced in House
  3. 2015-05-19Referred to the House Committee on Energy and Commerce.